Tag Archives: DOVA

Dova Pharmaceuticals (DOVA) Upgraded by Zacks Investment Research to “Hold”

Dova Pharmaceuticals (NASDAQ:DOVA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “

Get Dova Pharmaceuticals alerts:

DOVA has been the topic of several other research reports. BidaskClub downgraded Dova Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 9th. ValuEngine upgraded Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Evercore ISI assumed coverage on Dova Pharmaceuticals in a research note on Friday, March 23rd. They issued a “line” rating and a $29.00 price target for the company. Finally, Ladenburg Thalmann assumed coverage on Dova Pharmaceuticals in a research note on Thursday, April 26th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $32.00.

Shares of Dova Pharmaceuticals stock traded up $1.07 on Monday, hitting $26.30. The stock had a trading volume of 359,500 shares, compared to its average volume of 152,660. Dova Pharmaceuticals has a twelve month low of $26.00 and a twelve month high of $27.07. The company has a market capitalization of $711.27 million and a price-to-earnings ratio of -18.79.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Wednesday, May 9th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.05). sell-side analysts predict that Dova Pharmaceuticals will post -2.15 EPS for the current year.

Several hedge funds have recently modified their holdings of DOVA. The Manufacturers Life Insurance Company boosted its stake in shares of Dova Pharmaceuticals by 702.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock valued at $137,000 after buying an additional 4,163 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Dova Pharmaceuticals by 148.6% in the first quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after buying an additional 3,195 shares during the period. California State Teachers Retirement System bought a new stake in shares of Dova Pharmaceuticals in the third quarter valued at approximately $202,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Dova Pharmaceuticals in the third quarter valued at approximately $241,000. Finally, Virtus Fund Advisers LLC bought a new stake in shares of Dova Pharmaceuticals in the fourth quarter valued at approximately $318,000. Institutional investors and hedge funds own 26.66% of the company’s stock.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com